Figure 5.

sorafenib inhibits LPS-mediated activation of TLR4/stat3/SUMO1 pathway (A) Western blot analysis indicates that TLR4/stat3 signaling was repressed by sorafenib. HepG2 and HCCLM3 cells were incubated with 10 µm sorafeniib for 24 h. (B) q-PCR analysis reveals that sorafenib decreases TLR4 expression and represses LPS-induced TLR4 overexpression. (C) Western blot analysis indicates that LPS-induced activation of TLR4/stat3 signaling is repressed by sorafenib. LPS-treated HCCLM3 cells were cultured with or without 10 µm sofanib for 24 h. (D) Schematic diagram. Sorafenib decreases caspase-1 expression and suppresses LPS-induced caspase-1 overexpression through inhibiting TLR4/stat3/SUMO1 signaling cascades. Data are means ± SEM from 3 independent experiments, * means p < 0.05, ** means p < 0.01, *** means p < 0.001 by unpaired student T test.